Detalhe da pesquisa
1.
R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.
Br J Haematol
; 204(3): 849-860, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37996986
2.
Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.
Hematol Oncol
; 42(3): e3272, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38595316
3.
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Am J Hematol
; 99(4): 615-624, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38343151
4.
Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with CML.
Cancer Sci
; 114(3): 995-1006, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36336963
5.
Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.
Cancer Sci
; 114(12): 4643-4653, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37921363
6.
Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01.
Cancer Sci
; 114(5): 2098-2108, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36793248
7.
Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406.
Cancer Sci
; 114(8): 3461-3465, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37232264
8.
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
N Engl J Med
; 383(7): 617-629, 2020 08 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32786187
9.
Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan.
Jpn J Clin Oncol
; 53(7): 595-603, 2023 Jun 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37017320
10.
Feasibility and preliminary effectiveness of a psychosocial support program for adolescent and young adult cancer patients in clinical practice: a retrospective observational study.
Support Care Cancer
; 31(2): 146, 2023 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729199
11.
Prognostic value of the Kyoto Prognostic Index in higher-risk diffuse large B-cell lymphomas treated by upfront autologous stem cell transplantation in JCOG0908 trial.
Jpn J Clin Oncol
; 52(6): 583-588, 2022 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35353186
12.
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
Jpn J Clin Oncol
; 52(1): 29-38, 2022 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34739075
13.
Differences in the approaches of cancer specialists toward adolescent and young adult cancer care.
Pediatr Int
; 64(1): e15119, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35616182
14.
Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.
Int J Mol Sci
; 23(9)2022 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35563085
15.
Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study.
Cancer Sci
; 112(6): 2405-2415, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33728735
16.
Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies.
Cancer Sci
; 112(1): 331-338, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33075165
17.
A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
Cancer Sci
; 112(7): 2845-2854, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33942442
18.
Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma.
Cancer Sci
; 112(6): 2426-2435, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33792128
19.
Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study.
Jpn J Clin Oncol
; 51(1): 70-77, 2021 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33029633
20.
Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor.
Cancer Sci
; 111(10): 3714-3725, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33404088